CPHI
Income statement / Annual
Last year (2023), China Pharma Holdings, Inc.'s total revenue was $7.01 M,
a decrease of 13.48% from the previous year.
In 2023, China Pharma Holdings, Inc.'s net income was -$3.08 M.
See China Pharma Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$7.01 M |
$8.10 M |
$9.64 M |
$10.87 M |
$10.92 M |
$12.33 M |
$13.21 M |
$15.57 M |
$20.35 M |
$22.13 M |
| Cost of Revenue |
$7.29 M
|
$8.60 M
|
$9.29 M
|
$8.91 M
|
$9.44 M
|
$10.36 M
|
$10.74 M
|
$12.35 M
|
$18.89 M
|
$19.47 M
|
| Gross Profit |
-$281,085.00
|
-$493,916.00
|
$349,270.00
|
$1.95 M
|
$1.48 M
|
$1.97 M
|
$2.47 M
|
$3.22 M
|
$1.46 M
|
$2.67 M
|
| Gross Profit Ratio |
-0.04
|
-0.06
|
0.04
|
0.18
|
0.14
|
0.16
|
0.19
|
0.21
|
0.07
|
0.12
|
| Research and Development Expenses |
$240,080.00
|
$185,858.00
|
$318,964.00
|
$377,964.00
|
$229,637.00
|
$172,384.00
|
$90,474.00
|
$365,969.00
|
$961,897.00
|
$2.80 M
|
| General & Administrative Expenses |
$1.47 M
|
$1.89 M
|
$1.65 M
|
$1.82 M
|
$2.29 M
|
$1.95 M
|
$2.02 M
|
$2.27 M
|
$1.90 M
|
$1.72 M
|
| Selling & Marketing Expenses |
$780,328.00
|
$1.07 M
|
$1.50 M
|
$2.22 M
|
$2.35 M
|
$3.22 M
|
$3.46 M
|
$4.04 M
|
$4.29 M
|
$3.35 M
|
| Selling, General & Administrative Expenses |
$2.25 M
|
$2.87 M
|
$3.15 M
|
$4.04 M
|
$4.64 M
|
$5.77 M
|
$6.87 M
|
$7.39 M
|
$16.34 M
|
$36.42 M
|
| Other Expenses |
-$15,757.00
|
$93,851.00
|
$0.00
|
$115.19 B
|
$7.58 T
|
$0.00
|
$4.83 T
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$2.47 M
|
$3.15 M
|
$3.46 M
|
$4.42 M
|
$4.87 M
|
-$12.42 M
|
-$21.15 M
|
-$11.37 M
|
-$15.76 M
|
-$41.43 M
|
| Cost And Expenses |
$9.76 M
|
$5.54 M
|
$12.76 M
|
$13.33 M
|
$14.31 M
|
-$2.07 M
|
-$10.40 M
|
$978,027.00
|
$3.12 M
|
-$21.96 M
|
| Interest Income |
$6,602.00
|
$10,755.00
|
$3,035.00
|
$5,675.00
|
$27,527.00
|
$38,516.00
|
$64,414.00
|
$130,575.00
|
$119,925.00
|
$69,739.00
|
| Interest Expense |
$333,600.00
|
$434,619.00
|
$542,001.00
|
$294,159.00
|
$321,718.00
|
$451,258.00
|
$539,334.00
|
$849,557.00
|
$1.17 M
|
$785,804.00
|
| Depreciation & Amortization |
$2.75 M
|
$2.70 M
|
$3.09 M
|
$2.68 M
|
$2.93 M
|
$3.26 M
|
$3.29 M
|
$3.08 M
|
-$3.60 M
|
-$1.79 M
|
| EBITDA |
$8,436.00 |
-$837,689.00 |
$230,345.00 |
$106,852.00 |
-$17.45 M |
-$7.15 M |
-$15.32 M |
-$4.95 M |
-$10.58 M |
-$36.90 M |
| EBITDA Ratio |
0
|
-0.1
|
-0
|
0.02
|
-0.04
|
-0.06
|
-0.09
|
-0.07
|
-0.52
|
-1.57
|
| Operating Income Ratio |
-0.39
|
-0.44
|
-0.32
|
-0.23
|
-0.31
|
-0.32
|
-0.34
|
-0.27
|
-0.7
|
-1.65
|
| Total Other Income/Expenses Net |
-$326,998.00
|
-$423,864.00
|
-$538,966.00
|
-$288,484.00
|
-$17.31 M
|
-$6.89 M
|
-$14.66 M
|
-$4.68 M
|
-$1.15 M
|
-$2.93 M
|
| Income Before Tax |
-$3.08 M
|
-$3.97 M
|
-$3.40 M
|
-$2.87 M
|
-$20.70 M
|
-$10.86 M
|
-$19.15 M
|
-$8.87 M
|
-$15.35 M
|
-$39.47 M
|
| Income Before Tax Ratio |
-0.44
|
-0.49
|
-0.35
|
-0.26
|
-1.9
|
-0.88
|
-1.45
|
-0.57
|
-0.75
|
-1.78
|
| Income Tax Expense |
$0.00
|
$6.25 M
|
$542,001.00
|
$294,159.00
|
$321,718.00
|
$109,989.00
|
$122,631.00
|
$308,175.00
|
$60,439.00
|
$77,042.00
|
| Net Income |
-$3.08 M
|
-$10.22 M
|
-$3.94 M
|
-$3.16 M
|
-$21.02 M
|
-$10.75 M
|
-$19.28 M
|
-$9.18 M
|
-$15.41 M
|
-$26.05 M
|
| Net Income Ratio |
-0.44
|
-1.26
|
-0.41
|
-0.29
|
-1.92
|
-0.87
|
-1.46
|
-0.59
|
-0.76
|
-1.18
|
| EPS |
-0.91 |
-1.94 |
-0.85 |
-0.72 |
-4.82 |
-2.47 |
-4.42 |
-2.11 |
-3.54 |
-5.99 |
| EPS Diluted |
-0.91 |
-1.94 |
-0.85 |
-0.72 |
-4.82 |
-2.47 |
-4.42 |
-2.11 |
-3.54 |
-5.98 |
| Weighted Average Shares Out |
$3.38 M
|
$5.26 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
| Weighted Average Shares Out Diluted |
$3.38 M
|
$5.26 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
